TAP's Prevacid DTC Ad Targets Former Vioxx Users
This article was originally published in The Pink Sheet Daily
Executive Summary
The print ad, which ran two days after the COX-2 advisory committee review concluded, capitalizes on the number of patients seeking alternative arthritis therapies following Merck's withdrawal of Vioxx. Committee members discussed use of a PPI with older NSAIDs as an alternative to coxib therapy.
You may also be interested in...
Pfizer Celebrex Continued Marketing Supported By FDA Cmte.
Committee finds celecoxib has cardiovascular side effects but may be safer than some other COX-2 inhibitors. Cardiovascular events may occur only at higher doses used for non-arthritis patients, some committee members suggest.
Nexium Approved For Lowering Risk Of NSAID-Related Ulcers
The supplemental approval allows AstraZeneca to position Nexium as an alternative to switching patients to a COX-2 to reduce the risk of gastric ulcers associated with continuous NSAID therapy. Nexium NSAID-related ulcer "healing" indication is "approvable."
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?